7. North America Intravitreal Injectables Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
7.3. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
7.4.Intravitreal Injectables Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
7.4.1.1.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
7.4.1.2.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
7.4.1.3.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8. UK and European Union Intravitreal Injectables Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.3. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.Intravitreal Injectables Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.1.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.2.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.3.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.4.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.5.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
8.4.1.6.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9. Asia Pacific Intravitreal Injectables Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.3. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.Intravitreal Injectables Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.1.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.2.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.3.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.4.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.5.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
9.4.1.6.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
10. Latin America Intravitreal Injectables Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
10.3. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
10.4.Intravitreal Injectables Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
10.4.1.1.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
10.4.1.2.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
10.4.1.3.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
11. Middle East and Africa Intravitreal Injectables Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
11.3. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
11.4.Intravitreal Injectables Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
11.4.1.1.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
11.4.1.2.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Intravitreal Injectables Market: By Indication, 2022-2032, USD (Million)
11.4.1.3.2. Intravitreal Injectables Market: By Drug Class, 2022-2032, USD (Million)
12. Company Profile
12.1. Allergan, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Alimera Sciences
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bristol-Myers Squibb Company
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Eyetech, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. F. Hoffmann-La Roche Ltd
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Genentech, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Regeneron Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. ThromboGenics, Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Valeant Pharmaceuticals International, Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives